JP6463745B2 - イコチニブ含有皮膚外用医薬組成物及びその応用 - Google Patents

イコチニブ含有皮膚外用医薬組成物及びその応用 Download PDF

Info

Publication number
JP6463745B2
JP6463745B2 JP2016521612A JP2016521612A JP6463745B2 JP 6463745 B2 JP6463745 B2 JP 6463745B2 JP 2016521612 A JP2016521612 A JP 2016521612A JP 2016521612 A JP2016521612 A JP 2016521612A JP 6463745 B2 JP6463745 B2 JP 6463745B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
base
icotinib
mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016521612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532659A5 (https=
JP2016532659A (ja
Inventor
インシアン ワン，
インシアン ワン，
シューチュン ユアン，
シューチュン ユアン，
イェンピン ワン，
イェンピン ワン，
シャオジン フー，
シャオジン フー，
ユンイェン フー，
ユンイェン フー，
Original Assignee
ベータ ファーマシューティカルズ カンパニー リミテッド
ベータ ファーマシューティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベータ ファーマシューティカルズ カンパニー リミテッド, ベータ ファーマシューティカルズ カンパニー リミテッド filed Critical ベータ ファーマシューティカルズ カンパニー リミテッド
Publication of JP2016532659A publication Critical patent/JP2016532659A/ja
Publication of JP2016532659A5 publication Critical patent/JP2016532659A5/ja
Application granted granted Critical
Publication of JP6463745B2 publication Critical patent/JP6463745B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016521612A 2013-10-11 2014-10-11 イコチニブ含有皮膚外用医薬組成物及びその応用 Expired - Fee Related JP6463745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/085042 2013-10-11
CN2013085042 2013-10-11
PCT/CN2014/088344 WO2015051763A1 (zh) 2013-10-11 2014-10-11 一种含埃克替尼的皮肤外用药物组合物及其应用

Publications (3)

Publication Number Publication Date
JP2016532659A JP2016532659A (ja) 2016-10-20
JP2016532659A5 JP2016532659A5 (https=) 2017-11-24
JP6463745B2 true JP6463745B2 (ja) 2019-02-06

Family

ID=52812537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521612A Expired - Fee Related JP6463745B2 (ja) 2013-10-11 2014-10-11 イコチニブ含有皮膚外用医薬組成物及びその応用

Country Status (13)

Country Link
US (2) US20160235757A1 (https=)
EP (1) EP3056206A4 (https=)
JP (1) JP6463745B2 (https=)
AU (1) AU2014334222B2 (https=)
BR (1) BR112016007627A2 (https=)
CA (1) CA2926874C (https=)
HK (1) HK1213813A1 (https=)
IL (1) IL245015A0 (https=)
NZ (1) NZ718802A (https=)
RU (1) RU2698796C2 (https=)
SG (1) SG11201602826VA (https=)
TW (1) TWI630921B (https=)
WO (1) WO2015051763A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102270538B1 (ko) * 2013-06-09 2021-06-29 베타 파머수티컬 컴퍼니 리미티드 이코티닙 포스페이트의 신규한 다형체 형태 및 이의 용도
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
CN116829152A (zh) * 2021-02-02 2023-09-29 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
CN116492293A (zh) * 2022-01-25 2023-07-28 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618933A2 (pt) * 2005-11-24 2016-09-13 Basf Se método para produzir uma molécula efetora que se liga à queratina, molécula efetora que se liga à queratina, uso das moléculas efetoras que se ligam à queratina, composto, e, dermocosmético
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
EP2392576B1 (en) 2008-07-08 2016-02-17 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
GB201010954D0 (en) * 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
MX2013004296A (es) * 2010-10-21 2013-09-26 Cadila Healthcare Ltd Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.

Also Published As

Publication number Publication date
EP3056206A4 (en) 2017-07-05
SG11201602826VA (en) 2016-05-30
IL245015A0 (en) 2016-05-31
WO2015051763A1 (zh) 2015-04-16
AU2014334222B2 (en) 2017-03-09
RU2698796C2 (ru) 2019-08-30
CA2926874A1 (en) 2015-04-16
CA2926874C (en) 2018-12-11
US20190321369A1 (en) 2019-10-24
AU2014334222A1 (en) 2016-05-05
NZ718802A (en) 2017-09-29
EP3056206A1 (en) 2016-08-17
TW201513894A (zh) 2015-04-16
RU2016118063A (ru) 2017-11-16
BR112016007627A2 (pt) 2017-08-01
JP2016532659A (ja) 2016-10-20
TWI630921B (zh) 2018-08-01
US20160235757A1 (en) 2016-08-18
HK1213813A1 (zh) 2016-07-15

Similar Documents

Publication Publication Date Title
AU2025226848A1 (en) Ionic Liquid Compositions For Treatment Of Rosacea
JPWO2005060935A1 (ja) 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
JP5859981B2 (ja) 担体組成物
JP2002526447A (ja) アルキルフェニルピリドンの局所製剤
JP6463745B2 (ja) イコチニブ含有皮膚外用医薬組成物及びその応用
Wen et al. Orexin A induces autophagy in HCT-116 human colon cancer cells through the ERK signaling pathway
KR20120107963A (ko) 담체 조성물
WO2022022434A1 (zh) 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
WO2008150929A1 (en) Topical compositions comprising a macromolecule and methods of using same
WO2021023099A1 (zh) 一种马钱子碱凝胶制剂及其制备方法
CN103893184A (zh) 包含活性剂的局部药物组合物
JP2022188061A (ja) Ｖｅｇｆ阻害剤の局所投与による皮膚障害の処置
CN105101966A (zh) 一种含埃克替尼的皮肤外用药物组合物及其应用
CN1171789A (zh) 6－[三唑基[3－(三氟甲基)苯基]甲基]－2－喹啉酮和喹啉硫酮
WO2024125322A1 (zh) 防治过敏性和/或炎症性疾病的双嘧达莫及其制剂
WO2019044670A1 (ja) ざ瘡様疾患を治療又は予防するための皮膚外用組成物
KR20160061425A (ko) 이코티닙-함유 국소 피부 약학 조성물 및 이의 용도
TW201740977A (zh) 用於緩解及治療搔癢病之方法
RU2396081C1 (ru) Фармацевтическая композиция для лечения дерматозов, поддающихся глюкокортикостероидной терапии, и способ ее получения
CN101180028B (zh) 金刚烷基甲氧基二苯基丙烯酸用于治疗痤疮的用途
JP2022531154A (ja) 炎症により引き起こされる自己免疫性皮膚疾患を治療するための化合物及びその使用
RU2563811C1 (ru) Фармацевтическая композиция для лечения грибковых заболеваний
EP3758699A1 (en) Compositions and methods for treating cutaneous fibrosis
JP2020533369A (ja) チモキノン含有組成物の調製法
CN117860670A (zh) 一种千层纸素外用制剂及其在银屑病治疗上的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181211

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190104

R150 Certificate of patent or registration of utility model

Ref document number: 6463745

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees